voriconazole

Voriconazole (UK-109496) is a triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 [CYP3A].

Voriconazole is a triazole antifungal compound utilized for the treatment of invasive fungal infections. It holds a significant position in the antifungal compound library and is characterized by a high degree of pharmacokinetic variability both between individuals and within the same individual. Voriconazole is primarily indicated for treating invasive fungal infections with broad efficacy.

Voriconazole N-oxide is a major metabolite of the triazole antifungal voriconazole . It is formed via oxidation of voriconazole by the cytochrome P450 (CYP) isoforms CYP3A4 and CYP2C19.

Voriconazole (UK-109496) camphorsulfonate, a second-generation broad-spectrum triazole antifungal compound, inhibits fungal ergosterol biosynthesis by targeting the P450-mediated demethylation of 14-alpha-lanosterol.

Voriconazole-d3 is a deuterated compound of Voriconazole. Voriconazole has a CAS number of 137234-62-9. Voriconazole is a triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.

(±)-Voriconazole-d3 (Mixture of Enantiomers) is a deuterated compound of (±)-Voriconazole. (±)-Voriconazole has a CAS number of 188416-29-7. (±)-Voriconazole ((±)-UK-109496) is a relative configuration of Voriconazole. Voriconazole is an antifungal agent [1].

CYP51-IN-20 (compound 5b), an antifungal agent, effectively inhibits CYP51 and exhibits significant activity against Candida albicans ATCC 10231. It suppresses the ERG11 (Cyp51) gene expression and markedly curtails the morphological transformation from yeast to hyphae. Furthermore, when combined with Voriconazole, CYP51-IN-20 synergistically occupies the entire CYP51 binding site, enhancing its inhibitory impact in the Glechoma moth model.